Since we did not perform corresponding tumor genome sequencing in our cohort, it is difficult to reach definite conclusions, but our ctDNA profiling results suggest that a CTNNB1 mutation might not have a large impact on the efficacy of combination immunotherapy in HCC patients. This evidence concerns the gene CTNNB1 and neoplasm.